Pump Science

@stevencuttama fixed

@pumpdotscience how can $venom earn "human" even tho haven't got verified?🤔

It's been a while since the last time I visit you @pumpdotscience , I saw several compounds that kinda odd 🤔

@Polymarket .@RobertKennedyJr @PeptideList @BowTiedUM @maxmarchione @PeptidePartners @bryan_johnson

since there is not @Polymarket for it yet will there will be a reclassification of at least one peptide from category 2->1 by may 1st?

Just in: SMER28 + Omipalisib extends C. elegans lifespan by 16.67% 🥳 @pumpdotscience

WORMS x.com/i/broadcasts/1…

@ColinTCrypto @benjileibo absolute clown

@benjileibo Low time frame price action can change quite frequently. I'm not flip-flopping. I've been talking about the same support/resistance level for a while now.

Where we're at. $BTC Reclaim $71.8k and a relief rally can return to the menu, but that must happen first.

@frankdegods not so fast

how crazy would this be

@anomalie_blue .@HairDAO_

6 months treatment with a shampoo containing 1% caffeine & 1% dimethylglycine sodium salt resulted in significant (p<0.001) increases in hair count, hair density, and % anagen hairs in a study of 154 men (Celleno, 2025). Caffeine has been shown to increase cAMP levels and promote cellular energy, while DMG has been shown to reduce inflammation & oxidative stress and improve local microcirculation.

@frankdegods now he listens

peptides are like claude code for your cells

Rapamycin Longevity Lab: Partnering with Metformin Ventures x.com/i/broadcasts/1…

great things rise together!

what’s coming next? you basically get paid for having erections.

@youngtarcin shocker

@pumpdotscience yes I do

DO YOU LIKE SEX? if so, BLUPILL is live with updates on its sexual health product x.com/i/broadcasts/1…

Our core mission at Rapamycin Longevity Lab (@omipalRLL) is to take mTOR inhibitors to the next level by developing combinational therapies. We are particularly interested in exploring the life-extending effects of combining mTOR inhibition with glucose regulation. To accelerate this research we are proud to announce a new partnership with Metformin Ventures (@longevityVentur) on @pumpdotscience! This collaboration brings us together with @LinusPeters, the visionary founder of Metformin Ventures and the Swedish Longevity Cluster. Linus has long been a driving force in the longevity community, organizing different events dedicated to the goal of solving aging. With our missions perfectly aligned we are ready to push the boundaries of human longevity together. We’re kicking things off with a livestream this Friday. So come and meet Linus and see how we’re planning to move the needle on aging.

things are happening 👀 BLUPILL stream + project update with @pumpdotscience tuesday 24 feb 11:00 est / 17:00 cet

@BlupillAging @ParrasAlbert i hope they're paying in $BLUPILL to make these

tomorrow, together with Vivoarchitect and @ParrasAlbert, we are presenting the BLUPILL project 💙

nature.com/articles/s4158… The first FDA approved clinical trial testing rejuvenation with partial cellular reprogramming factors is about to start! This is a huge moment for the longevity field. Partial cellular reprogramming has the potential to not just slow biological aging, but reverse aspects of age-related decline. This is not theory; it has been shown in preclinical studies, including data from Life Bioscience's founder, David Sinclair's lab, demonstrating restoration of vision in partially blind mice. This 5 year clinical trial will test whether pulsed delivery of three cellular reprogramming factors (O, S, K) can restore vision in individuals with forms of optic neuropathy and glaucoma -- common drivers of vision loss. Keep in mind, this technology relies on a form of gene therapy: cost, scalability, and accessibility are major bottlenecks. Long-term safety in humans is still a major outstanding question. The time horizon for this particular technology to reach the masses (if it succeeds in restoring vision) is 1-2 decades at a minimum. A small price to pay for the potential massive impact of rejuvenation. Even more reason for optimism. @OMIPALRLL and @ReprogLab are working hard in parallel to develop and validate chemical reprogramming factors that capture the rejuvenative impact with small molecules, peptides, familiar factors that can greatly reduce cost, improve safety profile, and accelerate time to market and accessibility. Not just for restoring vision -- but age-related diseases that impact the brain, immune system, heart, and muscles. Potentially even prevention. 2026 has started with a breakneck pace, and the future of longevity is bright! The fundamental strategy of today: 1) Track and support labs/companies driving the breakthrough science 2) Stay healthy enough for long enough to engage with the rejuvenative technologies already in the pipeline.